Here are 71 Mass. life science firms presenting at J.P. Morgan
Dozens of Massachusetts biotech leaders will be heading to San Francisco this upcoming week for the 2025 J.P. Morgan ...
The Pharma Letter11h
The week in pharma: action, reaction and insight – week to January 10
Among significant news last week, the US Food and Drug Administration (FDA) required Agios Pharmaceuticals to amend the label ...
Strategic Shift and Uncertainties Lead to Hold Rating for Repare Therapeutics
Bloom Burton analyst David Martin PhD has maintained their neutral stance on RPTX stock, giving a Hold rating on January 10.Stay Ahead of the ...
Repare Therapeutics Announces Strategic Changes and Financial Update
Repare Therapeutics Inc. (NASDAQ: RPTX) disclosed significant strategic adjustments in a recent SEC 8-K filing. The precision oncology company declared preliminary unaudited financial data, indicating ...